Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BMS-777607 |
| Synonyms | |
| Therapy Description |
BMS-777607 (ASLAN002) is a small molecule that inhibits MET, MST1R (RON), TYRO3, and AXL, resulting in decreased downstream pathway activation, potentially resulting in decreased tumor cell growth and metastasis (PMID: 19260711, PMID: 20515943, PMID: 24233399, PMID: 26555154). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BMS-777607 | ASLAN002|BMS777607|BMS 777607 | AXL Inhibitor 30 MET Inhibitor 59 RON Inhibitor 11 TYRO3 Inhibitor 7 | BMS-777607 (ASLAN002) is a small molecule that inhibits MET, MST1R (RON), TYRO3, and AXL, resulting in decreased downstream pathway activation, potentially resulting in decreased tumor cell growth and metastasis (PMID: 19260711, PMID: 20515943, PMID: 24233399, PMID: 26555154). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MST1R pos PIK3CA H1047R | estrogen-receptor positive breast cancer | predicted - sensitive | BMS-777607 | Preclinical - Pdx | Actionable | In a preclinical study, BMS-777607 (ASLAN002) inhibited tumor growth in patient-derived xenograft (PDX) models of estrogen-receptor positive breast cancer harboring PIK3CA H1047R and expressing the short isoform of MST1R (RON) (PMID: 26289070). | 26289070 |
| MST1R act mut | breast cancer | predicted - sensitive | BMS-777607 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, BMS-777607 (ASLAN002) inhibited tumor growth in breast cancer cell line xenograft models expressing a constitutively active short isoform of MST1R (RON) (PMID: 26289070). | 26289070 |
| MST1R pos PIK3CA wild-type | estrogen-receptor positive breast cancer | predicted - sensitive | BMS-777607 | Preclinical - Pdx | Actionable | In a preclinical study, BMS-777607 (ASLAN002) inhibited tumor growth in patient-derived xenograft (PDX) models of estrogen-receptor positive breast cancer with wild-type PIK3CA and expressing the short isoform of MST1R (RON) (PMID: 26289070). | 26289070 |
| AXL positive | glioblastoma | sensitive | BMS-777607 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, BMS-777607 inhibited Axl phosphorylation, resulted in decreased viability of glioblastoma multiforme cell lines in culture and in cell line xenograft models (PMID: 26848524). | 26848524 |
| MST1R pos PIK3CA E545K | breast cancer | predicted - sensitive | BMS-777607 | Preclinical - Cell culture | Actionable | In a preclinical study, BMS-777607 decreased viability of a breast cancer cell line expressing the constitutively active short isoform of MST1R (RON) and PIK3CA E545K in culture (PMID: 26289070). | 26289070 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|